Carfentanil is a β‐arrestin‐biased agonist at the μ opioid receptor
British Journal of Pharmacology · 2023
DOI: 10.1111/bph.16084 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Nokomis Ramos-Gonzalez und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Potassium Channels, Inwardly Rectifying. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Background and Purpose The illicit use of fentanyl‐like drugs (fentanyls), which are μ opioid receptor agonists, and the many overdose deaths that result, has become a major problem. Fentanyls are very potent in vivo, leading to respiratory depression and death. However, the efficacy and possible signalling bias of different fentanyls is not clearly known. Here, we compared the relative efficacy and bias of a series of fentanyls. Experimental Approach For agonist signalling bias and efficacy measurements, Bioluminescence Resonance Energy Transfer experiments were undertaken in HEK293T cells transiently transfected with μ opioid receptors, to assess Gi protein activation and β‐arrestin 2 recruitment. Agonist‐induced cell surface receptor loss was assessed using an enzyme‐linked immunosorbent assay, whilst agonist‐induced G protein‐coupled inwardly rectifying potassium channel current activation was measured electrophysiologically from rat locus coeruleus slices. Ligand poses in the μ opioid receptor were determined in silico using molecular dynamics simulations. Key Results Relative to the reference ligand DAMGO, carfentanil was β‐arrestin‐biased, whereas fentanyl, sufentanil and alfentanil did not display bias. Carfentanil induced potent and extensive cell surface receptor loss, whilst the marked desensitisation of G protein‐coupled inwardly rectifying potassium channel currents in the continued presence of carfentanil in neurones was prevented by a GRK2/3 inhibitor. Molecular dynamics simulations suggested unique interactions of carfentanil with the orthosteric site of the receptor that could underlie the bias. Conclusions and Implications Carfentanil is a β‐arrestin‐biased opioid drug at the μ receptor. It is uncertain how such bias influences in vivo effects of carfentanil relative to other fentanyls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
- Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
- School of Biochemistry, University of Bristol, Bristol, UK.
ORCID-Profile: Graeme Henderson, Eamonn Kelly
Förderung
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Ramos-Gonzalez, N., Groom, S., Sutcliffe, K. J., Bancroft, S., Bailey, C. P., Sessions, R. B., Henderson, G., & Kelly, E. (2023). Carfentanil is a β‐arrestin‐biased agonist at the μ opioid receptor. British Journal of Pharmacology. https://doi.org/10.1111/bph.16084
Vancouver
Ramos-Gonzalez N, Groom S, Sutcliffe KJ, Bancroft S, Bailey CP, Sessions RB, et al. Carfentanil is a β‐arrestin‐biased agonist at the μ opioid receptor. British Journal of Pharmacology. 2023. doi:10.1111/bph.16084
BibTeX
@article{RamosGonzalez2023,
author = {Ramos-Gonzalez, Nokomis and Groom, Sam and Sutcliffe, Katy J and Bancroft, Sukhvinder and Bailey, Chris P and Sessions, Richard B and Henderson, Graeme and Kelly, Eamonn},
title = {Carfentanil is a β‐arrestin‐biased agonist at the μ opioid receptor},
journal = {British Journal of Pharmacology},
year = {2023},
doi = {10.1111/bph.16084}
}
EUVIMED